 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...6789101112131415161718» |
- | Leukeran (chlorambucil) / GSK
Preclinical, Journal: In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. (Pubmed Central) - Feb 27, 2019
In pharmacokinetic studies, the mean plasma Cmax of chlorambucil was 0.06 μM. Results suggest that metronomic chlorambucil in dogs does not achieve plasma concentrations high enough to cause direct cytotoxic or growth inhibitory effects on either glioma or endothelial cells.
- |||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Feb 4, 2019
P3, N=212, Active, not recruiting, Sponsor: Pharmacyclics LLC.
Results suggest that metronomic chlorambucil in dogs does not achieve plasma concentrations high enough to cause direct cytotoxic or growth inhibitory effects on either glioma or endothelial cells. Trial primary completion date: Oct 2017 --> Mar 2018
- | Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 10, 2019
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Oct 2017 --> Mar 2018 Trial completion date: Dec 2018 --> Sep 2019
- ||||||| Leukeran (chlorambucil) / GSK
Trial completion: Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) (clinicaltrials.gov) - Jan 8, 2019
P3, N=450, Completed, Sponsor: Celgene
Trial completion date: Dec 2018 --> Sep 2019 Active, not recruiting --> Completed
- || Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Jan 8, 2019
P=N/A, N=49, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 26, 2018
P3, N=445, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2018 --> Aug 2018
- |||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 12, 2018
P3, N=600, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Nov 2018 --> Aug 2018 Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Sep 2018 --> Nov 2019
- | Gazyva (obinutuzumab) / Roche, Biogen
Trial completion, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 29, 2018
P3, N=979, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2018 --> Nov 2020 | Trial primary completion date: Sep 2018 --> Nov 2019 Active, not recruiting --> Completed
- | Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Oct 11, 2018
P3, N=232, Active, not recruiting, Sponsor: Pharmacyclics LLC.
Active, not recruiting --> Completed Trial completion date: Nov 2018 --> Apr 2023 | Trial primary completion date: Nov 2018 --> Apr 2023
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Oct 11, 2018
P1, N=38, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Nov 2018 --> Apr 2023 | Trial primary completion date: Nov 2018 --> Apr 2023 Active, not recruiting --> Completed
- | Arzerra (ofatumumab) / Novartis, Genmab
Trial completion, Trial completion date, Monotherapy: COMPLEMENT 1: Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 7, 2018
P3, N=447, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2018
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Enrollment change: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Jul 6, 2018
P1, N=38, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2018 Recruiting --> Active, not recruiting | N=60 --> 38
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
New trial: GAIRI: Gazyva Infusion Reaction Investigation (clinicaltrials.gov) - May 21, 2018
P=N/A, N=104, Recruiting, Sponsor: Healthy Future
- || lenalidomide / Generic mfg.
Trial completion date, Trial primary completion date: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Apr 26, 2018
P2, N=254, Active, not recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting | N=60 --> 38 Trial completion date: Mar 2018 --> Jul 2019 | Trial primary completion date: Mar 2018 --> Oct 2018
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Mar 30, 2018
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2018 --> Jul 2019 | Trial primary completion date: Mar 2018 --> Oct 2018 Trial completion date: Mar 2019 --> Sep 2018 | Trial primary completion date: Mar 2019 --> Sep 2018
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Phase classification: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Mar 29, 2018
P, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2019 --> Sep 2018 | Trial primary completion date: Mar 2019 --> Sep 2018 Phase classification: P=N/A --> P
- Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 20, 2018
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Phase classification: P=N/A --> P Trial completion date: Dec 2017 --> Dec 2018
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial: GLOW: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov) - Mar 11, 2018
P3, N=200, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || lenalidomide / Generic mfg.
Trial primary completion date: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Dec 4, 2017
P2, N=254, Active, not recruiting, Sponsor: Celgene
Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Mar 2018
- |||| Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Oct 24, 2017
P3, N=232, Active, not recruiting, Sponsor: Pharmacyclics LLC.
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Feb 2018 --> Nov 2018
- ||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Enrollment closed, Enrollment change, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 19, 2017
P3, N=600, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Feb 2018 --> Nov 2018 Recruiting --> Active, not recruiting | N=450 --> 600
- | Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting --> Active, not recruiting | N=450 --> 600 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Sep 13, 2017
P=N/A, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Oct 2019 --> Apr 2020
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Aug 22, 2017
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2019 --> Apr 2020 Trial primary completion date: Mar 2018 --> Mar 2019
- |||| Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 31, 2017
P3, N=979, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Oct 2018 --> Dec 2016
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 15, 2017
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Oct 2018 --> Dec 2016 Trial primary completion date: Mar 2017 --> Nov 2017
- || lenalidomide / Generic mfg.
Trial primary completion date: Sprint: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Apr 25, 2017
P2, N=254, Active, not recruiting, Sponsor: Celgene
Trial primary completion date: Mar 2017 --> Nov 2017 Trial primary completion date: Mar 2017 --> Dec 2017
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Feb 20, 2017
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- ||||| Calquence (acalabrutinib) / AstraZeneca
Enrollment closed, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Feb 16, 2017
P3, N=535, Active, not recruiting, Sponsor: Acerta Pharma BV
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 8, 2016
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Mar 2017
- | Rituxan (rituximab) / Roche
Enrollment change: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - Nov 2, 2016
P4, N=18, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2016 --> Mar 2017 N=26 --> 18
- ||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 18, 2016
P3, N=979, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=26 --> 18 Recruiting --> Active, not recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New trial: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Sep 26, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 2, 2016
P3, N=445, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Leukeran (chlorambucil) / GSK
Trial completion, Metastases: Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 11, 2016
P3, N=205, Completed, Sponsor: German CLL Study Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed, Trial primary completion date, Combination therapy: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - Jul 28, 2016
P2, N=112, Active, not recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2016
- |||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment open, Trial primary completion date, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jul 20, 2016
P3, N=950, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2016 Active, not recruiting --> Recruiting | Trial primary completion date: May 2016 --> Oct 2018
- Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Active, not recruiting --> Recruiting | Trial primary completion date: May 2016 --> Oct 2018 Trial primary completion date: Sep 2015 --> Sep 2016
- |||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Trial primary completion date, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 31, 2016
P3, N=450, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Mar 2018 --> Sep 2018
- | Rituxan (rituximab) / Roche
Trial completion: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - May 6, 2016
P4, N=26, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Sep 2018 Active, not recruiting --> Completed
- ||||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 5, 2016
P3, N=978, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Calquence (acalabrutinib) / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Apr 27, 2016
P3, N=510, Recruiting, Sponsor: Acerta Pharma BV
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2019 --> Dec 2019
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Apr 6, 2016
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2019 --> Dec 2019 Trial primary completion date: Sep 2017 --> Mar 2018
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 3, 2016
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Sep 2017 --> Mar 2018 Trial primary completion date: Feb 2016 --> Aug 2016
- |||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
Enrollment open, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 15, 2016
P3, N=450, Recruiting, Sponsor: TG Therapeutics, Inc.
Trial primary completion date: Feb 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- |||||||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap
New P3 trial, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 24, 2015
P3, N=450, Not yet recruiting, Sponsor: TG Therapeutics, Inc.
- Rituxan (rituximab) / Roche
Trial primary completion date: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status (clinicaltrials.gov) - Nov 10, 2015
P4, N=26, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2019 --> Feb 2016
- ||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Oct 30, 2015
P3, N=212, Active, not recruiting, Sponsor: Pharmacyclics
Trial primary completion date: Feb 2019 --> Feb 2016 Recruiting --> Active, not recruiting
- Ukoniq (umbralisib) / TG Therap
Enrollment closed, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 8, 2015
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting